Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × pertuzumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 152 HER2-positive Breast Cancer 15 Neoplasms 12 Neoplasm Metastasis 9 Prostatic Neoplasms 6 Ovarian Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Stomach Neoplasms 4 Pancreatic Neoplasms 4 Inflammatory Breast Neoplasms 4 Colonic Neoplasms 4 Brain Neoplasms 4 Triple Negative Breast Neoplasms 3 Solid Tumor 3 Pathologic Complete Response 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Hematologic Neoplasms 3 HER2-positive Early Breast Cancer 3 Endometrial Neoplasms 3 Breast Neoplasms, Male 3 Biliary Tract Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Urinary Bladder Neoplasms 2 Salivary Gland Neoplasms 2 Rectal Neoplasms 2 Lung Neoplasms 2 Locally Advanced Breast Cancer 2 HER2-positive Metastatic Breast Cancer 2 Gastrointestinal Neoplasms 2

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡